📊 Midday Market Take

Hey there, glad you could check in with us this Wednesday afternoon. The S&P 500, Nasdaq, and Dow are all pushing higher, up 0.75%, 1.11%, and 0.95% respectively, making for a pretty clean sweep across the board.

Tech is doing the heavy lifting today, with the Nasdaq leading the pack and semiconductor names looking particularly frisky heading into the close. Keep your eyes on any Fed speaker headlines this afternoon, because even a stray hawkish comment could take some of the air out of this rally fast.

Immunovant, Inc.

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina.

3 Reasons to Watch IMVT

• An Arthritis Drug Just Changed Everything. Immunovant surged over 35% in a single session after news broke around a rheumatoid arthritis drug development, sending the stock into breakout territory. When one catalyst can move a clinical-stage biotech that much in one day, the market is telling you something loud and clear.
• Q4 Earnings Drop With Momentum Already Built In. The company just reported fourth quarter and full fiscal year results, giving investors a fresh look under the hood right as the stock is hitting new highs. Earnings calls at this stage of a biotech run tend to either confirm the story or kill it, and the timing here makes it worth paying close attention.
• A Year of 137% Gains and Still Climbing. IMVT is up nearly 138% over the past year, and the 30-day and 90-day returns are both sitting above 38%, meaning this is not a one-day wonder. That kind of multi-timeframe consistency in a clinical-stage immunology name signals that institutional money has been steadily building a position, not just chasing headlines.

Top Market Headlines

These 2 Computer and Technology Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

The Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert (Ad)

Luke Lango was ranked America's #1 stock picker in 2020. He was mentored by two hedge fund billionaires from the Soros network and trained at Caltech. His readers have had the chance to see gains as high as AMD +8,500%... Nvidia +5,000%... Tesla +3,500%... Palantir +1,000%... and Apple +890%.

Is DAVE INC (DAVE) Outperforming Other Business Services Stocks This Year?

Here is how Dave Inc. (DAVE) and UL Solutions Inc. (ULS) have performed compared to their sector so far this year.

UK stocks rise as weak labour data eases rate hike concerns

UK equities moved higher on Tuesday after weaker labour market data eased concerns over an immediate interest rate hike from the Bank of England.

BREAKING UPDATE: Elon Musk Just Filed the SpaceX IPO (Ad)

It was supposed to be confidential... But it's become the worst-kept secret on Wall Street. Right now, 21 banks are lining up to underwrite the $1.75 TRILLION deal - JPMorgan, Goldman Sachs, Morgan Stanley. June is the target date for launch... That gives everyday Americans a small window to get positioned before Wall Street insiders gobble up all the profits.

Are Computer and Technology Stocks Lagging KLA (KLAC) This Year?

Here is how KLA (KLAC) and Arrow Electronics (ARW) have performed compared to their sector so far this year.

Iran Desperately Needs This From America (Ad)

Trump is about to cut Iran off at the knees. One tiny North Carolina town supplies 80% of the world's most critical semiconductor material. Business Insider calls it "crucial to make chips that power everything from smartphones to data centers." When Trump bans exports, Iran's tech infrastructure crumbles — and every chipmaker on Earth is forced to relocate to U.S. soil. Morgan Stanley estimates the reshoring boom triggers a $10 trillion transformation. A handful of U.S. companies stand to capture most of it.